Difference between revisions of "CNS5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(Created page with "Welcome! For assignments, please see the "Author" column below (highlighted blue). If empty (no name is present), please volunteer to create content for that disease! To vol...") |
|||
(12 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
For assignments, please see the "Author" column below (highlighted blue). | For assignments, please see the "Author" column below (highlighted blue). | ||
+ | |||
If empty (no name is present), please volunteer to create content for that disease! | If empty (no name is present), please volunteer to create content for that disease! | ||
− | To volunteer, please [Contact us] with your page of interest. | + | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> |
− | + | {| class="wikitable" style="margin:auto" | |
− | ==WHO Classification of Tumours of the Central Nervous System (5th Edition) Content | + | |+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> |
− | |||
|- | |- | ||
− | !'''Disease'''!!'''Page Type'''!!'''Author''' | + | !'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author''' |
!'''Date Assigned to Author''' | !'''Date Assigned to Author''' | ||
!'''Target Completion Date''' | !'''Target Completion Date''' | ||
Line 17: | Line 17: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | | | + | |CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]] | ||
|Disease | |Disease | ||
|Meenakshi Mehrotra | |Meenakshi Mehrotra | ||
Line 28: | Line 48: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Oligodendroglioma, IDH- | + | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] |
+ | |Disease | ||
+ | |Riley Lochner (trainee), Shashi Shetty (mentor) | ||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
Line 37: | Line 59: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Glioblastoma, IDH- | + | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] |
+ | |Disease | ||
+ | |Meenakshi Mehrotra | ||
| | | | ||
| | | | ||
Line 44: | Line 68: | ||
|LS | |LS | ||
| | | | ||
− | |Moved from " | + | |Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added |
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] |
+ | |Disease | ||
+ | |Scott Smith | ||
|6/27/2023 | |6/27/2023 | ||
| | | | ||
Line 55: | Line 81: | ||
|2021 template added (page created 6/27/23) | |2021 template added (page created 6/27/23) | ||
|- | |- | ||
− | |Angiocentric | + | |[[CNS5:Angiocentric_glioma|Angiocentric glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 64: | Line 92: | ||
| | | | ||
|- | |- | ||
− | |Polymorphous | + | |[[CNS5:Polymorphous_low-grade_neuroepithelial_tumour_of_the_young|Polymorphous low-grade neuroepithelial tumour of the young]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 73: | Line 103: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 82: | Line 114: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] |
+ | |Disease | ||
+ | |Laveniya Satgunaseelan (Linda Cooley - previous version) | ||
| | | | ||
| | | | ||
Line 91: | Line 125: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_hemispheric_glioma,_H3_G34-mutant|Diffuse hemispheric glioma, H3 G34-mutant]] |
+ | |Disease | ||
+ | |Xiaolin (Lynn) Hu | ||
|2/21/2022 | |2/21/2022 | ||
| | | | ||
Line 100: | Line 136: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] |
+ | |Disease | ||
+ | |Madina Sukhanova | ||
|10/28/2022 | |10/28/2022 | ||
| | | | ||
Line 109: | Line 147: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Infant- | + | |[[CNS5:Infant-type_hemispheric_glioma|Infant-type hemispheric glioma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
| | | | ||
| | | | ||
Line 116: | Line 157: | ||
| | | | ||
| | | | ||
− | |||
|- | |- | ||
− | |Pilocytic | + | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] |
+ | |Disease | ||
+ | |Jeremy Pulvers | ||
|9/13/2022<br /> | |9/13/2022<br /> | ||
| | | | ||
Line 127: | Line 169: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |High- | + | |[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 136: | Line 180: | ||
| | | | ||
|- | |- | ||
− | |Pleomorphic | + | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 145: | Line 191: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Subependymal | + | |[[CNS5:Subependymal_giant_cell_astrocytoma|Subependymal giant cell astrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 154: | Line 202: | ||
| | | | ||
|- | |- | ||
− | |Chordoid | + | |[[CNS5:Chordoid_glioma|Chordoid glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 163: | Line 213: | ||
| | | | ||
|- | |- | ||
− | |Astroblastoma, MN1- | + | |[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 172: | Line 224: | ||
| | | | ||
|- | |- | ||
− | |Ganglioglioma||Disease | + | |[[CNS5:Ganglioglioma|Ganglioglioma]] |
+ | |Disease | ||
+ | |Leila Moayed-Aloei | ||
|6/30/2022 | |6/30/2022 | ||
| | | | ||
Line 181: | Line 235: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Gangliocytoma||Disease | + | |[[CNS5:Gangliocytoma|Gangliocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 190: | Line 246: | ||
| | | | ||
|- | |- | ||
− | |Desmoplastic | + | |[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 199: | Line 257: | ||
| | | | ||
|- | |- | ||
− | |Dysembryoplastic | + | |[[CNS5:Dysembryoplastic_neuroepithelial_tumour|Dysembryoplastic neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 208: | Line 268: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_glioneuronal_tumour_with_oligodendroglioma-like_features_and_nuclear_clusters|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 217: | Line 279: | ||
| | | | ||
|- | |- | ||
− | |Papillary | + | |[[CNS5:Papillary_glioneuronal_tumour|Papillary glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 226: | Line 290: | ||
| | | | ||
|- | |- | ||
− | |Rosette- | + | |[[CNS5:Rosette-forming_glioneuronal_tumour|Rosette-forming glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 235: | Line 301: | ||
| | | | ||
|- | |- | ||
− | |Myxoid | + | |[[CNS5:Myxoid_glioneuronal_tumour|Myxoid glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 244: | Line 312: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 253: | Line 323: | ||
| | | | ||
|- | |- | ||
− | |Multinodular and | + | |[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 262: | Line 334: | ||
| | | | ||
|- | |- | ||
− | |Dysplastic | + | |[[CNS5:Dysplastic_cerebellar_gangliocytoma_(Lhermitte-Duclos_disease)|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 271: | Line 345: | ||
| | | | ||
|- | |- | ||
− | |Central | + | |[[CNS5:Central_neurocytoma|Central neurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 280: | Line 356: | ||
| | | | ||
|- | |- | ||
− | |Extraventricular | + | |[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 289: | Line 367: | ||
| | | | ||
|- | |- | ||
− | |Cerebellar | + | |[[CNS5:Cerebellar_liponeurocytoma|Cerebellar liponeurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 298: | Line 378: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 307: | Line 389: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 316: | Line 400: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 325: | Line 411: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_ependymoma|Posterior fossa ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 334: | Line 422: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_A_(PFA)_ependymoma|Posterior fossa group A (PFA) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 343: | Line 433: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_B_(PFB)_ependymoma|Posterior fossa group B (PFB) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 352: | Line 444: | ||
| | | | ||
|- | |- | ||
− | |Spinal | + | |[[CNS5:Spinal_ependymoma|Spinal ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 361: | Line 455: | ||
| | | | ||
|- | |- | ||
− | |Spinal | + | |[[CNS5:Spinal_ependymoma,_MYCN-amplified|Spinal ependymoma, MYCN-amplified]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 370: | Line 466: | ||
| | | | ||
|- | |- | ||
− | |Myxopapillary | + | |[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 379: | Line 477: | ||
| | | | ||
|- | |- | ||
− | |Subependymoma||Disease | + | |[[CNS5:Subependymoma|Subependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 388: | Line 488: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 3 (CHOROID PLEXUS TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 406: | Line 519: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_choroid_plexus_papilloma|Atypical choroid plexus papilloma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Choroid_plexus_carcinoma|Choroid plexus carcinoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 415: | Line 541: | ||
| | | | ||
|- | |- | ||
− | |Medulloblastoma, WNT- | + | |CHAPTER 4 (EMBRYONAL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] | ||
+ | |Disease | ||
+ | |Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | ||
|9/20/21 | |9/20/21 | ||
| | | | ||
Line 424: | Line 572: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Medulloblastoma, SHH- | + | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-wildtype|Medulloblastoma, SHH-activated and TP53-wildtype]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_histologically_defined|Medulloblastoma, histologically defined]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 433: | Line 616: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_teratoid/rhabdoid_tumour|Atypical teratoid/rhabdoid tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 442: | Line 627: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cribriform_neuroepithelial_tumour|Cribriform neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 451: | Line 638: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Embryonal_tumour_with_multilayered_rosettes|Embryonal tumour with multilayered rosettes]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_neuroblastoma,_FOXR2-activated|CNS neuroblastoma, FOXR2-activated]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_embryonal_tumour_NEC/NOS|CNS embryonal tumour NEC/NOS]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 460: | Line 682: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 5 (PINEAL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineocytoma|Pineocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 478: | Line 713: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 487: | Line 724: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineoblastoma|Pineoblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 496: | Line 735: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 505: | Line 746: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 514: | Line 757: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Schwannoma|Schwannoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 532: | Line 788: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Neurofibroma|Neurofibroma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 541: | Line 799: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Perineurioma|Perineurioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 550: | Line 810: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 559: | Line 821: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 568: | Line 832: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 577: | Line 843: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 586: | Line 854: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 7 (MENINGIOMA) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Meningioma|Meningioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 604: | Line 885: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 622: | Line 916: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangiomas_and_vascular_malformations|Haemangiomas and vascular malformations]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 631: | Line 927: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangioblastoma|Haemangioblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 640: | Line 938: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rhabdomyosarcoma|Rhabdomyosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 649: | Line 949: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Intracranial_mesenchymal_tumour,_FET::CREB_fusion-positive|Intracranial mesenchymal tumour, FET::CREB fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 658: | Line 960: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 667: | Line 971: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 676: | Line 982: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Ewing_sarcoma|Ewing sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 685: | Line 993: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 694: | Line 1,004: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chondrosarcoma|Chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 703: | Line 1,015: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chordoma|Chordoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 712: | Line 1,026: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 9 (MELANOCYTIC TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 730: | Line 1,057: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 739: | Line 1,068: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Primary | + | |[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 757: | Line 1,099: | ||
| | | | ||
|- | |- | ||
− | |Immunodeficiency- | + | |[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 766: | Line 1,110: | ||
| | | | ||
|- | |- | ||
− | |Lymphomatoid | + | |[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 775: | Line 1,121: | ||
| | | | ||
|- | |- | ||
− | |Intravascular | + | |[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 784: | Line 1,132: | ||
| | | | ||
|- | |- | ||
− | |MALT | + | |[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 793: | Line 1,143: | ||
| | | | ||
|- | |- | ||
− | |Other | + | |[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 802: | Line 1,154: | ||
| | | | ||
|- | |- | ||
− | |Anaplastic | + | |[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 809: | Line 1,163: | ||
|MS | |MS | ||
| | | | ||
− | |2021 template added | + | |2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"? |
+ | |- | ||
+ | |[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 820: | Line 1,220: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 829: | Line 1,231: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 11 (GERM CELL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 847: | Line 1,262: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 12 (TUMOURS OF THE SELLAR REGION |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 865: | Line 1,293: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 874: | Line 1,304: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 883: | Line 1,315: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 892: | Line 1,326: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_blastoma|Pituitary blastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 901: | Line 1,337: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 13 (METASTASES TO THE CNS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 919: | Line 1,368: | ||
| | | | ||
|- | |- | ||
− | |Metastases to the | + | |[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 928: | Line 1,379: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Neurofibromatosis | + | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] |
+ | |Disease | ||
+ | |Ngoni Faya (trainee) + Madina Sukhanova | ||
| | | | ||
| | | | ||
Line 946: | Line 1,410: | ||
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Neurofibromatosis | + | |[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 955: | Line 1,421: | ||
| | | | ||
|- | |- | ||
− | |Schwannomatosis||Disease | + | |[[CNS5:Schwannomatosis|Schwannomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 964: | Line 1,432: | ||
| | | | ||
|- | |- | ||
− | |Von Hippel-Lindau | + | |[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 973: | Line 1,443: | ||
| | | | ||
|- | |- | ||
− | |Tuberous | + | |[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 982: | Line 1,454: | ||
| | | | ||
|- | |- | ||
− | |Li-Fraumeni | + | |[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 991: | Line 1,465: | ||
| | | | ||
|- | |- | ||
− | |Cowden | + | |[[CNS5:Cowden_syndrome|Cowden syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,000: | Line 1,476: | ||
| | | | ||
|- | |- | ||
− | |Constitutional | + | |[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 1,009: | Line 1,487: | ||
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] |
+ | |Disease | ||
+ | |Jennifer Laffin | ||
|8/22/2023 | |8/22/2023 | ||
| | | | ||
Line 1,018: | Line 1,498: | ||
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Naevoid | + | |[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,027: | Line 1,509: | ||
| | | | ||
|- | |- | ||
− | |Rhabdoid | + | |[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,036: | Line 1,520: | ||
| | | | ||
|- | |- | ||
− | |Carney | + | |[[CNS5:Carney_complex|Carney complex]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,045: | Line 1,531: | ||
| | | | ||
|- | |- | ||
− | |DICER1 | + | |[[CNS5:DICER1_syndrome|DICER1 syndrome]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 1,054: | Line 1,542: | ||
|NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,063: | Line 1,553: | ||
| | | | ||
|- | |- | ||
− | |Melanoma- | + | |[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,072: | Line 1,564: | ||
| | | | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,081: | Line 1,575: | ||
| | | | ||
|- | |- | ||
− | |BAP1 | + | |[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,090: | Line 1,586: | ||
| | | | ||
|- | |- | ||
− | |Fanconi | + | |[[CNS5:Fanconi_anaemia|Fanconi anaemia]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,099: | Line 1,597: | ||
| | | | ||
|- | |- | ||
− | |ELP1- | + | |[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,108: | Line 1,608: | ||
| | | | ||
|- | |- | ||
− | |} | + | |} |
Latest revision as of 14:00, 25 February 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.